Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| ReadCoor | 2020 | Series B | $27.0M | Cambridge |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 101 | ReadCoor | Series B | $27.0M | Cambridge, United States |
| 102 | Genetron Health | Series D | $71.0M | Beijing, China |
| 103 | Metacrine | Debt Financing | $50.0M | San Diego, United States |
| 104 | Medeor Therapeutics | Grant | $18.8M | South San Francisco, United States |
| 105 | Outpost Medicine | Series A | $20.0M | Indianapolis, United States |
Leader in true multi-omic spatial sequencing
Genetron Health is a world-leading expert in precision medicine.
Metacrine is a clinical-stage bio pharmaceutical company focused on building an innovative pipeline of best-in-class drugs.
Medeor Therapeutics is a biotechnology company that dedicates to dedicates to the development of personalized cellular immunotherapies.
Outpost Medicine is a biopharmaceutical company
Vivo Capital has invested in 105 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Vivo Capital's top investment sectors include Biotechnology, Medical, Pharmaceutical, Health Care, Clinical Trials. The firm invests across 9 different industry categories.
Among tracked funding rounds, Genetron Health received $71.0M in a Series D round. Vivo Capital's total known invested capital is $5.6B.
Vivo Capital's average investment size is $78.6M across its portfolio of 105 companies.
Recent Vivo Capital portfolio additions include ReadCoor. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors